This report explores the relationship between nutrition and treatment effectiveness in schizophrenia, emphasizing how dietary deficiencies and antipsychotic medications influence patient outcomes. It highlights that individuals with schizophrenia often present with poor nutritional status—particularly low levels of folate, B vitamins, vitamin D, vitamin C, and omega-3 fatty acids—even before treatment begins. Antipsychotics may further deplete key nutrients and increase oxidative stress, compounding symptom burden and metabolic risk. Clinical trials suggest that targeted supplementation with antioxidants, B-complex vitamins, and omega-3s can reduce psychiatric symptoms, improve cognition, and enhance treatment response, particularly in early-stage illness or high-risk populations. The report concludes that routine nutritional screening, personalized supplementation, and integration of dietitians into psychiatric care represent promising strategies to optimize schizophrenia treatment.
Download the full report here.
